Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Repurposing Existing Medicines Is Key Part Of Pandemic Solution, Industry Insists
Executive Summary
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
You may also be interested in...
Repurposing Initiatives Proposed To Unlock ‘Untapped Potential’ In Europe
Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.
Repurposing Initiatives Proposed To Unlock ‘Untapped Potential’ In Europe
Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.
Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.